ESR1 and in situ carcinoma: In contrast, the triple combination (CB839+ ERA+ CIS) overcame CIS-resistance by mediating a significant growth delay in HCC1806R tumors (P < 0.05, comparing CB839+ERA+CIS vs. CIS,Fig. 6F).